Código QR

Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors

Background Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.

Gardado en:
Principais autores: Mark Goldin, Kolton Smith, Ioannis Koulas, Tungming Leung, Mayuri Ravi, Sanjit Parhar, Sejal Shah, Kayla Floyd, Lori Ohanesian, Rachel Bain, Daniella Defonte, Kanta Ochani, Amanda Lin, Bhumi Patel, Nikolaos Tsaftaridis, Jack Jnani, Alex C. Spyropoulos
Formato: Artigo
Idioma:Inglês
Publicado: Georg Thieme Verlag KG 2024-04-01
Series:TH Open
Assuntos:
DOAC
critical bleeding
andexanet alfa
clinical pathway
thromboembolism
Acceso en liña:http://www.thieme-connect.de/DOI/DOI?10.1055/a-2306-0804
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares